Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of roflumilast for long-term cognitive sequelae after stroke
2020-003768-16Phase 2Completed
- Sponsor
- Hersenstichting
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stroke and post-stroke cognitive impairment (PSCI) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Verbal Word Learning Test delayed recall. Started Feb 2021; status: completed.
02
Drugs
roflumilast
03
Conditions
strokepost-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on 2020-003768-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003768-16.